GSK's Blenrep Combo Therapy Under EMA Review
Ticker: GLAXF · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, EMA, drug-review, oncology
Related Tickers: GSK
TL;DR
EMA's reviewing GSK's Blenrep combo for multiple myeloma - big potential win!
AI Summary
GSK plc announced on July 19, 2024, that the European Medicines Agency (EMA) has accepted for review a Type II variation application for Blenrep (belantamab mafodotin) in combination therapy for multiple myeloma. This application seeks to expand the existing marketing authorization for Blenrep.
Why It Matters
The EMA's acceptance for review is a crucial step towards potentially expanding Blenrep's use in treating multiple myeloma, which could significantly impact patient treatment options and GSK's revenue.
Risk Assessment
Risk Level: low — This filing is a routine notification of a regulatory review process, not a direct financial event or negative news.
Key Players & Entities
- GSK plc (company) — Registrant
- Blenrep (drug) — Product under review
- belantamab mafodotin (drug) — Active ingredient of Blenrep
- European Medicines Agency (EMA) (company) — Regulatory body reviewing application
- multiple myeloma (disease) — Condition Blenrep is intended to treat
- July 19, 2024 (date) — Date of announcement
FAQ
What specific combination therapies involving Blenrep are being reviewed by the EMA?
The filing states that the application is for Blenrep in 'combination therapy' but does not specify the exact drug combinations being reviewed.
What is the current marketing authorization status of Blenrep in Europe?
The filing indicates this is a Type II variation application to expand the *existing* marketing authorization, suggesting Blenrep is already approved for some indication.
What is the significance of a Type II variation application?
A Type II variation is a significant change to a marketing authorization, often related to new therapeutic indications, new formulations, or new administration routes, requiring a full review by the EMA.
When was Blenrep first approved by the EMA?
The filing does not provide the initial approval date for Blenrep, only that this is an application to expand its existing authorization.
What is the expected timeline for the EMA's review of this application?
The filing does not specify an expected timeline for the EMA's review process.
Filing Stats: 1,608 words · 6 min read · ~5 pages · Grade level 13.7 · Accepted 2024-07-19 07:08:00
Filing Documents
- a0215x.htm (6-K) — 53KB
- 0001654954-24-009128.txt ( ) — 54KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: July 19, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc